Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 06, 2023 06:00 ET | Source: BiondVax Pharmaceuticals Ltd.

BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics

JERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company, is pleased to announce today a change of its corporate name to...
March 03, 2023 14:07 ET | Source: InvestorBrandNetwork (IBN)

IBN Announces ‘Test. Optimize. Scale.’ Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research Institutes

LOS ANGELES, March 03, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN, a multifaceted financial news and publishing company for private and public entities, today announces that Amir Reichman, CEO...
December 13, 2022 08:17 ET | Source: InvestorBrandNetwork (IBN)

IBN Announces Latest Episode of The Stock2Me Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.

LOS ANGELES, Dec. 13, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to...
December 12, 2022 07:06 ET | Source: BiondVax Pharmaceuticals Ltd.

BiondVax Regains Nasdaq Compliance

JERUSALEM, Dec. 12, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and...
December 06, 2022 08:30 ET | Source: BiondVax Pharmaceuticals Ltd.

IBN (InvestorBrandNetwork) Coverage Initiated for BiondVax Pharmaceuticals Ltd.

LOS ANGELES, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing...
December 06, 2022 07:30 ET | Source: BiondVax Pharmaceuticals Ltd.

Professor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board

Jerusalem, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and commercializing...
November 30, 2022 09:15 ET | Source: BiondVax Pharmaceuticals Ltd.

BiondVax announces Third Quarter 2022 Financial Results and Provides Business Update

JERUSALEM, Nov. 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), which focuses on developing, manufacturing, and commercializing innovative...
November 29, 2022 07:00 ET | Source: BiondVax Pharmaceuticals Ltd.

BiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy

Hamsters infected with SARS-COV-2 and then treated with inhaled anti-COVID-19 NanoAbs demonstrated significantly less severe illness and faster recovery in comparison to infected hamsters treated with...
November 15, 2022 08:33 ET | Source: BiondVax Pharmaceuticals Ltd.

BiondVax Congratulates Dirk Görlich on $1.4 million WLA Prize in Life Sciences

JERUSALEM, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and...
November 10, 2022 16:00 ET | Source: BiondVax Pharmaceuticals Ltd.

BiondVax Announces Plan to Implement ADS Ratio Change

JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and...